ePrints

Cybrids for Mitochondrial DNA Pharmacogenomics

Lookup NU author(s): Dr Aurora Gomez Duran

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Several key components of the oxidative phosphorylation system are coded in mitochondrial DNA. In humans, the mutation rate of the mitochondrial genome is higher than that of nuclear DNA. Some of these mutations can modify the interaction of mitochondrial DNA-encoded products with different therapeutic drugs. Several of these mutations have survived evolution, therefore generating different mitochondrial DNA genetic backgrounds. Thus, personalized medicine approaches must consider these particular interactions. However, before incorporating this knowledge into patient treatments, cellular and molecular studies are required. In this review, we discuss the cybrid model as a tool for this type of analysis, along with the pitfalls and improvements that are necessary before the translation of such models to medical practice.

Publication metadata

Author(s): Iglesias E, Llobet L, Pacheu-Grau D, Gómez-Durán A, Ruiz-Pesini E

Publication type: Article

Publication status: Published

Journal: Drug Development Research

Year: 2012

Volume: 73

Issue: 8

Pages: 453-460

Print publication date: 18/10/2012

ISSN (print): 0272-4391

ISSN (electronic): 1098-2299

Publisher: John Wiley & Sons, Inc.

URL: http://dx.doi.org/10.1002/ddr.21037

DOI: 10.1002/ddr.21037

Altmetrics

Share